Roche signed a definitive agreement to acquire Poseida Therapeutics, a deal that includes Poseida’s portfolio of CAR T-cell therapy candidates being developed for multiple sclerosis (MS) and other diseases. Poseida and Roche have been collaborating since 2022 on cell therapies for people with blood cancer. The companies…

By studying pairs of identical twins, researchers have identified a population of immune cells whose early activation and migration into the brain might contribute to multiple sclerosis (MS) onset. MS patients showed an altered profile of a population of immune cells called CD8 T-cells in the blood relative to…

Iaso Biotherapeutics has received the green light from the U.S. Food and Drug Administration (FDA) to start clinical trials of its investigational CAR T-cell therapy equecabtagene autoleucel (eque-cel) in people with multiple sclerosis (MS). The FDA’s clearance of the company’s investigational new drug (IND) application makes MS the…

Using a newly developed molecular analysis, a research team has discovered previously unknown subsets of immune cells and genes that may play a role in multiple sclerosis (MS) and other immune-mediated diseases. “We discovered new types of helper T cells as well as genes related to immune disorders. We…

Researchers have identified nearly two dozen genes that help to control the movement of immune cells into the brain and spinal cord during multiple sclerosis (MS). Findings may form the basis for the further development of MS treatments that aim to reduce disease activity by blocking the infiltration…

Changes in the gene activity within immune T-cells explain why women with multiple sclerosis (MS) improve during pregnancy, a study reports. Gene activity changes during and after pregnancy were highly similar between MS patients and healthy women. Many of the genes whose activity was altered during pregnancy were associated…

Long-term treatment with Ocrevus (ocrelizumab) doesn’t change the diversity of T-cells — those needed to mount effective immune responses against foreign pathogens — in people with relapsing multiple sclerosis (MS) patients, a small study shows. Consistent with its mechanism of B-cell depletion, however, Ocrevus did reduce the molecular…

The way Ocrevus (ocrelizumab) affects immune cell profiles of people with multiple sclerosis (MS) varies depending on what treatments they were on previously, a new study shows. Understanding these differences could help to optimize treatment approaches for MS patients considering Ocrevus, scientists say. The study, “…

Following an autologous hematopoietic stem cell transplant (aHSCT) in people with multiple sclerosis (MS), the population of “naïve” T-cells — components of the immune system that enable the body to fight off new, unrecognized infections — is completely renewed but some memory T-cells, which are responsible for rapid responses…

NexImmune is working with the National Institute of Neurological Disorders and Stroke (NINDS) to develop cell therapies for people with immunological disorders associated with certain viral infections, namely the Epstein-Barr virus (EBV) and human T-cell leukemia virus type 1 (HTLV-1). A history of infection with EBV — mostly…

People with multiple sclerosis (MS) have significantly more T-cells equipped with receptors that specifically recognize the Epstein-Barr virus (EBV) than do healthy individuals, a study revealed. Notably, no such differences were detected for T-cells with receptors specifically against other viruses. These findings add to previous data highlighting EBV infection…

An experimental oral therapy called TRE-515 significantly reduced disease severity and the growth of the abnormal immune cells that drive multiple sclerosis (MS) in two mouse models of the disease, a study found. Notably, the efficacy of Trethera Corp.’s potential treatment, administered either in a preventive or therapeutic…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Trethera Corporation’s experimental oral therapy TRE-515 for demyelinating optic neuritis, an eye condition that may progress to multiple sclerosis (MS) or occur during the disease course. The first-in-class therapy is expected to lessen the inflammation…

An eight-week calorie-restricted diet plan — known as intermittent fasting — led to immune and metabolic changes among people with multiple sclerosis (MS) in a small pilot clinical trial, data show. The findings could underlie some of the proposed benefits of calorie restriction on MS disease course, the researchers…

Unusual growth in an immune cell class called myeloid cells is evident in the bone marrow of people with multiple sclerosis (MS), and these cells likely contribute to the inflammation that drives the disease, according to a new study. Experiments in mice suggest that myelin-reactive T-cells can migrate to the bone…

A Phase 1/2 clinical trial is evaluating the safety and effectiveness of a cutting-edge immunotherapy called extracorporeal photopheresis in people with multiple sclerosis (MS). The study, dubbed PHOMS (NCT05168384), is enrolling up to 45 adults with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) at a…

Researchers have identified four new brain proteins that are targeted by inflammatory T-cells in multiple sclerosis (MS), which could aid in the development of more specific and safer treatments for people with the condition. The study, “Identification of four novel T cell autoantigens and personal autoreactive profiles in…

Atara Biotherapeutics plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active, progressive forms of multiple sclerosis (MS). Whether efforts for these trials will go forward, however, depends on positive results from an interim analysis of the Phase 2 portion of the…

Molecular “traps” made by neutrophils, a type of white blood cell, to fight bacteria may contribute to the excessive inflammatory activity of T-helper 17 immune T-cells, which are known to play a role in autoimmune diseases like multiple sclerosis (MS). Neutrophils are equipped with a number of biochemical tools…

KAT7, an enzyme known to regulate gene activity, is essential for the process of teaching immune T-cells to correctly identify the body’s molecules and cells as ‘self’ — a process that goes awry in multiple sclerosis (MS) and other autoimmune diseases. This enzyme is also critical for training T-cells…

Tevogen Bio is planning to make use of its virus-fighting immune cell technology and turn it against Epstein-Barr virus (EBV), a common virus thought to greatly increase the risk of multiple sclerosis (MS). The technology employs off-the-shelf cytotoxic T-cells — a type of white blood cell that can…

A new subset of type 3 innate lymphoid cells (ILC3s) — a type of immune cell known mostly for its anti-inflammatory and immunosuppressive effects in the gut — infiltrates the brain and promotes the abnormal immune attacks that drive multiple sclerosis (MS), according to a study in a mouse model…

National MS Society Supports Stem Cell Transplant for Select, Aggressive RRMS Bravo! This statement is welcome after the recommendation of National Multiple Sclerosis Society advisers that autologous hematopoietic stem cell transplant, or AHSCT, could be useful for people younger than 50 and recently diagnosed with MS. Now, how long…

An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging…

A component of yeast cell walls — called MGCP — prevented disease in a mouse model of multiple sclerosis (MS) by activating anti-inflammatory immune T-cells while suppressing inflammatory T-cells, a study showed. This work also supporting the microbiome’s role in affecting inflammation in autoimmune diseases like MS. “We have…

Repertoire Immune Medicines and Yale University have entered a research collaboration to identify what type of antigens are activating immune T-cells in patients with multiple sclerosis (MS). Antigens are molecular structures, such as a portion of a protein or a specific chain of sugars, that trigger an immune…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…

A group of helper T-cell (Th cells), a type of immune cell, could be responsible for the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS), with important implications for diagnosing and treating SPMS, a new study found. The study, “Involvement of cytotoxic Eomes-expressing…

For a first time, an immune-modulating antibody will be given via nasal administration to treat a person with secondary progressive multiple sclerosis (SPMS). The U.S. Food and Drug Administration (FDA) approved a request to use the antibody — a fully human anti-CD3 monoclonal antibody called foralumab — under an…

A Phase 1 clinical trial investigating ANK-700 as a means to restore immune tolerance to myelin in people multiple sclerosis (MS) has begun dosing participants. Currently recruiting at a single site in Tennessee, the trial (NCT04602390) is expected to enroll up to 40 patients with relapsing-remitting…